

## Hydrix announces long term development partnership with Scandinavian Realheart

Hydrix Limited ('Hydrix' or 'the Company') (ASX: HYD) is pleased to announce it has been selected to develop the control system for Swedish company [Scandinavian Realheart](#) AB's Total Artificial Heart (TAH). Realheart is developing the world's first four-chamber Total Artificial Heart and is publicly listed on the Nasdaq First North Growth Market.

This first stage of a multi-stage program will be delivered in financial year 2023 generating revenue of approximately A\$2 million in that year. This product development will help accelerate Realheart's TAH system to in-patient clinical trials in 2024. This partnership with Realheart affirms Hydrix's credentials in cardiovascular technology development.

The Realheart TAH aims to treat advanced stage heart failure, completely replacing the diseased heart. The device aims to mimic the function and form of the natural heart, gently circulating blood through the atria and ventricles with its unique atrioventricular plane. The special design aims to minimise the risk of stroke, bleeding, and anaemia, which are common side effects of heart pumps in use today.

Hydrix has been providing Mechanical Circulatory Support (MCS) controller development services to companies for more than 10-years. This includes Ventricular Assist Devices (VAD) that help a struggling heart to pump blood, and Total Artificial Heart (TAH), a complete heart replacement for where a donor heart is unavailable, or unsuitable. Hydrix's skills and experience are an ideal fit for Realheart as they develop the world's first four-chamber total artificial heart.

Ina Laura Perkins, CEO of Realheart said:

*"The controller for our TAH is technically very advanced, and for those who will live with our artificial heart in the future, its design must be extremely easy to use. We want even the very first clinical trial patient to be able to leave the hospital with an external controller that has advanced safety critical features and is very intuitive to use."*

*"We have been collaborating closely with Hydrix for the past few years. We are convinced that their experience in safety critical controller systems design is also characterised by a strong focus on human user needs experience which will ensure we can offer our patients and carers, the best controller for meeting these needs and expectations."*

Michael Trieu, Hydrix Services, General Manager said:

*"This is a strong endorsement of Hydrix as a best-in-class product development partner for clients building disruptive Class III cardiovascular technologies. Realheart is at the forefront of total artificial heart development, which aims to extend the life of, and the quality of life of, people with advanced cardiovascular disease."*

*"Realheart selected Hydrix for its leadership and deep experience developing disruptive Class III safety critical technologies for medical devices including TAHs and Ventricular Assist Devices (VADs). Hydrix know-how and platform technologies help de-risk and accelerate Mechanical Circulatory Support (MCS)"*

*developers to mature their cardiac technologies with greater confidence and reliability; from bench-top prototype to in-human trials to commercial release.”*

Gavin Coote, Executive Chairman, Hydrix said:

*“A core strategic focus across the Hydrix Group is bringing disruptive cardiovascular technologies to market. Today, we are delivering on this strategy by partnering with companies like Scandinavian Realheart to develop tomorrow’s replacement heart, as well as, making venture investments in, and bringing to market, products such as Angel Medical Systems implantable heart attack alert device, The Guardian.*

*“Hydrix Services first half year-on-year client revenue growth of +40%, coupled with a healthy qualified sales pipeline and client contract wins such as Scandinavian Realheart, strengthens the company’s outlook entering FY2023.”*

**-ENDS-**

**Authorisation:** This announcement is authorised for release by the Board of Directors of Hydrix Limited.

**Contact Details:** For more information, please contact:

**Company Enquiries:**

Gavin Coote

Executive Chairman

[info@hydrix.com](mailto:info@hydrix.com)

+61 3 9550 8100

**Media Enquires:**

Rod North

Managing Director, Bourse Communications

[rod@boursecommunications.com.au](mailto:rod@boursecommunications.com.au)

+61 3 9510 8309

**About Hydrix Limited**

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix purpose is to improve a billion lives. The company leverages its powerful product innovation capability across multiple growth platforms. These platforms include **Hydrix Services** offers design and engineering expertise to help transform client ideas into commercial products; **Hydrix Ventures** invests in high potential early stage medtech clients; and **Hydrix Medical** sells and markets disruptive cardiovascular technologies that aim to solve unmet market needs and improve patient quality of life.